Zdrowie i gospodarka · 4.11.2003
Draft Guidance for Industry on Pharmacogenomic Data Submissions; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Pharmacogenomic Data Submissions." The draft guidance provides recommendations to sponsors holding investigational new drug applications (INDs), new drug applications (NDAs), and biologics license applications (BLAs) on what pharmacogenomic data to submit to the agency during the drug development process, the format of submissions, and how the data will be used in regulatory decisionmaking. The draft guidance is intended to facilitate scientific progress in the area of pharmacogenomics, which should enable the FDA to use pharmacogenomic data in regulatory policies and decision making.